Therapeutic Research

Abstract

To analyze the time course of blood glucose profile in type 1 outpatients, who switch from glargine or detemir to degludec, by continuous glucose monitoring （CGM） at the time of switching（Group A ; n＝19） and 1 –3 months after switching（ Group B; n＝10）. CGM end points related to the dawn phenomenon were: 1） Δblood glucose（BG）①：The mean pre –breakfast increment in BG level : Δ（FPG–BGmin, 2 –6AM） 2） ΔBG②：The mean 2h pre –breakfast increment in BG level: Δ（FPG–FPG2h prior） A significant correlation between ΔBG①and C–peptide after switching to degludec. A strong correlation between ΔBG①, ΔBG②and nocturnal hypoglycemia. Those who experienced diurnal hypoglycemia after switching to degludec tend to display greater ΔBG①. Titration of degludec according to the target fasting peripheral blood glucose（FPG） in type 1 subjects requires attention to a risk of having hypoglycaemia, as their need in insulin are generally less at night and day time.